MU
Micron Technology
-- 86.945 TSLA
Tesla
-- 432.999 NVDA
NVIDIA
-- 132.021 QUBT
Quantum Computing
-- 15.709 NUKK
Nukkleus
-- 52.620 
NEWS
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
Thursday, 19th December at 9:00 am
Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company's business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Moderna to utilize Personalis' ImmunoID NeXT Platform® and technology for V940/mRNA-4157, an investigational individualized neoantigen therapy (INT), being jointly developed by Merck and Moderna.
Merck has agreed to purchase $50 million of Personalis common stock in a private placement at a price of $3.56 per share, which was the last reported closing price of Personalis' common stock as reported on The Nasdaq Global Market on December 18, 2024. Following the closing, Merck will own approximately 14 million shares of Personalis common stock, representing an approximately 16.5 percent beneficial ownership interest in Personalis.
Thursday, 19th December at 9:00 am
Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company's business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Moderna to utilize Personalis' ImmunoID NeXT Platform® and technology for V940/mRNA-4157, an investigational individualized neoantigen therapy (INT), being jointly developed by Merck and Moderna.
Merck has agreed to purchase $50 million of Personalis common stock in a private placement at a price of $3.56 per share, which was the last reported closing price of Personalis' common stock as reported on The Nasdaq Global Market on December 18, 2024. Following the closing, Merck will own approximately 14 million shares of Personalis common stock, representing an approximately 16.5 percent beneficial ownership interest in Personalis.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment